SCHEMBL9724496

SCHEMBL9724496

C=CC[N+](C)(C)N1c2ccccc2Sc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.46
KMT2A Q03164 2/20 0.44
PTGS1 P23219 3/20 0.40
KDM1A O60341 3/20 0.40
PTGS2 P35354 2/20 0.40
NOX1 Q9Y5S8 1/20 0.40
BCHE P06276 4/20 0.38
CYP2D6 P10635 3/20 0.38
LMNA P02545 3/20 0.38
SLC22A1 O15245 2/20 0.38
PRNP P04156 2/20 0.38
CYP1A2 P05177 2/20 0.38
CHRM2 P08172 2/20 0.38
CHRM4 P08173 2/20 0.38
HTR1A P08908 2/20 0.38
CHRM5 P08912 2/20 0.38
ADRA2A P08913 2/20 0.38
CHRM1 P11229 2/20 0.38
DRD2 P14416 2/20 0.38
ADRA2B P18089 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL29392172 0.71 PTGS1 (0.54) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL29376932 0.71 KMT2A (0.52) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL39172 0.71 KMT2A (0.52) MAOAKMT2APTGS1KDM1APTGS2
Iodide SCHEMBL11442732 0.69 KMT2A (0.51) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL3235747 0.68 MAOA (0.58) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL272974 0.67 MAOA (0.52) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL31671101 0.67 MAOA (0.52) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL5865535 0.67 KMT2A (0.45) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL9724497 0.66 KDM1A (0.47) MAOAKMT2APTGS1KDM1APTGS2
SCHEMBL3466443 0.64 MAOA (0.48) MAOAKMT2APTGS1KDM1APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5104858-A Administering trans-flupenthiyol with doxorubicin; lack of antipsychotic activity reduces side effects YALE UNIVERSITY (US) 1992-04-14 US disclosed